Cargando…

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)

Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bérard, Ghislain, Guévremont, Chantal, Marcotte, Nathalie, Schroeder, Coleen, Bouchard, Nicole, Rajan, Raghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047395/
https://www.ncbi.nlm.nih.gov/pubmed/36975460
http://dx.doi.org/10.3390/curroncol30030247
_version_ 1785013911839309824
author Bérard, Ghislain
Guévremont, Chantal
Marcotte, Nathalie
Schroeder, Coleen
Bouchard, Nicole
Rajan, Raghu
author_facet Bérard, Ghislain
Guévremont, Chantal
Marcotte, Nathalie
Schroeder, Coleen
Bouchard, Nicole
Rajan, Raghu
author_sort Bérard, Ghislain
collection PubMed
description Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overall survival (OS), and immune-related adverse events (IRAEs); and compare outcomes between a fixed dose (FD) and a weight-based capped dose (WCD). Medical records of patients treated in one of Quebec’s four adult university teaching hospitals who received pembrolizumab between 1 November 2017 and 31 October 2019 were reviewed and followed until 29 February 2020. Two hundred and seventy-nine patients were included. The median real-world PFS and OS were 9.4 (95% CI, 6.6 to 11.2) and 17.3 months (95% CI, 12.9 to not reached), respectively. IRAEs causing delays or treatment interruptions were seen in 34.4% of patients. Initiating treatment with a FD (49 patients) or using a WCD (230 patients) does not appear to affect PFS, OS, or the occurrence of IRAEs. The use of a WCD strategy allowed approximately CAD 5.8 million in savings during the course of our study. These findings support the effectiveness and safety of pembrolizumab in a real-world setting. The use of a WCD does not appear to have a negative impact on patient outcomes.
format Online
Article
Text
id pubmed-10047395
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100473952023-03-29 Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study) Bérard, Ghislain Guévremont, Chantal Marcotte, Nathalie Schroeder, Coleen Bouchard, Nicole Rajan, Raghu Curr Oncol Article Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overall survival (OS), and immune-related adverse events (IRAEs); and compare outcomes between a fixed dose (FD) and a weight-based capped dose (WCD). Medical records of patients treated in one of Quebec’s four adult university teaching hospitals who received pembrolizumab between 1 November 2017 and 31 October 2019 were reviewed and followed until 29 February 2020. Two hundred and seventy-nine patients were included. The median real-world PFS and OS were 9.4 (95% CI, 6.6 to 11.2) and 17.3 months (95% CI, 12.9 to not reached), respectively. IRAEs causing delays or treatment interruptions were seen in 34.4% of patients. Initiating treatment with a FD (49 patients) or using a WCD (230 patients) does not appear to affect PFS, OS, or the occurrence of IRAEs. The use of a WCD strategy allowed approximately CAD 5.8 million in savings during the course of our study. These findings support the effectiveness and safety of pembrolizumab in a real-world setting. The use of a WCD does not appear to have a negative impact on patient outcomes. MDPI 2023-03-11 /pmc/articles/PMC10047395/ /pubmed/36975460 http://dx.doi.org/10.3390/curroncol30030247 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bérard, Ghislain
Guévremont, Chantal
Marcotte, Nathalie
Schroeder, Coleen
Bouchard, Nicole
Rajan, Raghu
Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title_full Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title_fullStr Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title_full_unstemmed Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title_short Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
title_sort descriptive analysis of first-line non-small cell lung cancer treatment with pembrolizumab in tumors expressing pd-l1 ≥ 50% in patients treated in quebec’s university teaching hospitals (dalp-first study)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047395/
https://www.ncbi.nlm.nih.gov/pubmed/36975460
http://dx.doi.org/10.3390/curroncol30030247
work_keys_str_mv AT berardghislain descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy
AT guevremontchantal descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy
AT marcottenathalie descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy
AT schroedercoleen descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy
AT bouchardnicole descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy
AT rajanraghu descriptiveanalysisoffirstlinenonsmallcelllungcancertreatmentwithpembrolizumabintumorsexpressingpdl150inpatientstreatedinquebecsuniversityteachinghospitalsdalpfirststudy